MARKET

CLSN

CLSN

Celsion Corp
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.420
+0.060
+2.54%
After Hours: 2.520 +0.1 +4.13% 17:56 05/27 EDT
OPEN
2.310
PREV CLOSE
2.360
HIGH
2.460
LOW
2.310
VOLUME
42.67K
TURNOVER
0
52 WEEK HIGH
23.25
52 WEEK LOW
2.230
MARKET CAP
17.18M
P/E (TTM)
-0.5457
1D
5D
1M
3M
1Y
5Y
BRIEF-Celsion Corp - On May 25, 2022, Co Entered Into At The Market Offering Agreement Pursuant To Which Co May Offer And Sell Shares Up To $7.5 Million
reuters.com · 2d ago
BRIEF-Celsion Corporation Reports First Quarter 2022 Financial Results
reuters.com · 05/16 12:19
Celsion: Q1 Earnings Insights
  Celsion (NASDAQ:CLSN) reported its Q1 earnings results on Monday, May 16, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/16 12:16
Celsion Q1 EPS $(1.82) Misses $(0.99) Estimate, Sales $125.00K Beat $100.00K Estimate
Celsion (NASDAQ:CLSN) reported quarterly losses of $(1.82) per share which missed the analyst consensus estimate of $(0.99) by 83.84 percent. This is a 34.81 percent decrease over losses of $(1.35) per share from the
Benzinga · 05/16 12:15
Celsion GAAP EPS of -$1.82 misses by $0.82, revenue of $0.13M beats by $0.02M
Celsion press release (NASDAQ:CLSN): Q1 GAAP EPS of -$1.82 misses by $0.82. Revenue of $0.13M (flat Y/Y) beats by $0.02M. The Company had $47.3 million in cash, investments and restricted cash as
Seekingalpha · 05/16 12:04
Celsion Corporation Reports First Quarter 2022 Financial Results and Provides Business Update
DNA Mediated Immunotherapy and Next-Generation Vaccine Programs Supported with a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. EDT LAWRENCEVILLE, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage ...
GlobeNewswire · 05/16 12:00
Earnings Scheduled For May 16, 2022
  Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand.
Benzinga · 05/16 09:18
Celsion Q4 2022 Earnings Preview
Celsion (NASDAQ:CLSN) is scheduled to announce Q4 earnings results on Monday, May 16th, before market open. The consensus EPS Estimate is -$1.02 and the consensus Revenue Estimate is $0.11M Looking
Seekingalpha · 05/13 14:56
More
No Data
Learn about the latest financial forecast of CLSN. Analyze the recent business situations of Celsion Corp through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
66.67%Buy
33.33%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CLSN stock price target is 32.67 with a high estimate of 45.00 and a low estimate of 16.00.
High45.00
Average32.67
Low16.00
Current 2.420
EPS
Actual
Estimate
-2.90-2.17-1.45-0.72
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 44
Institutional Holdings: 571.44K
% Owned: 8.05%
Shares Outstanding: 7.10M
TypeInstitutionsShares
Increased
6
78.67K
New
8
5.47K
Decreased
8
25.18K
Sold Out
18
55.00K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Chief Financial Officer/Executive Vice President/Secretary/IR Contact Officer
Jeffrey Church
Executive Vice President
Khursheed Anwer
Executive Vice President
Nicholas Borys
Director/Chief Executive Officer/President/Chairman
Michael Tardugno
Director
Stacy Lindborg
Director
Christine Pellizzari
Independent Director
Donald Braun
Independent Director
Augustine Chow
Independent Director
Frederick Fritz
Independent Director
Robert Hooper
No Data
No Data
About CLSN
Celsion Corporation (Celsion) is a clinical stage biotechnology company. The Company’s product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer and ThermoDox, a heat-activated liposomal encapsulation of doxorubicin for several cancer indications. Its GEN-1, an IL-12 DNA plasmid vector formed into nanoparticles with a lipopolymeric delivery system, is the product candidate designed via the TheraPlas platform technology. Its Lysolipid Thermally Sensitive Liposomes (LTSL) technology is a heat-sensitive liposomal formulation that targets disease with therapeutics in the presence of mild heat. Its TheraSilence technology delivers synthetically generated inhibitory RNA (RNAi) to regulate protein expression in target cells.

Webull offers kinds of Celsion Corporation stock information, including NASDAQ:CLSN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLSN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLSN stock methods without spending real money on the virtual paper trading platform.